Compounding Deal In Congress Allows Voluntary FDA Oversight Of Large-Scale Facilities
This article was originally published in The Pink Sheet Daily
Executive Summary
Compounders could submit to inspections, user fees and adverse event reporting, providing potential market advantage; Legislation, which includes track and trace draft bill, avoids compounding controversies and could be poised for swift passage.